Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.